1211-P: No Significant Change of Glucagon Level by Empagliflozin in Diabetic Mice

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 1211-P
Author(s):  
HIROMI SHIMODA ◽  
YUSUKE SEINO ◽  
TATSUHITO HIMENO ◽  
RIEKO INOUE ◽  
MIKIO MOTEGI ◽  
...  
Keyword(s):  
Diabetic Mice ◽  
Glucagon Level ◽  
Significant Change

Anti-Diabetic Activity of a Mineraloid Isolate, in vitro and in Genetically Diabetic Mice

2011 ◽  
Vol 81 (1) ◽  
pp. 34-42 ◽  
Author(s):  
Joel Deneau ◽  
Taufeeq Ahmed ◽  
Roger Blotsky ◽  
Krzysztof Bojanowski
Keyword(s):  
Dna Microarrays ◽  
Human Fibroblasts ◽  
Diabetic Animal ◽  
In Vitro Tests ◽  
Diabetic Mice ◽  
Fossil Material ◽  
Expression Of Genes ◽  
Enhanced Expression ◽  
Genetically Diabetic Mice

Type II diabetes is a metabolic disease mediated through multiple molecular pathways. Here, we report anti-diabetic effect of a standardized isolate from a fossil material - a mineraloid leonardite - in in vitro tests and in genetically diabetic mice. The mineraloid isolate stimulated mitochondrial metabolism in human fibroblasts and this stimulation correlated with enhanced expression of genes coding for mitochondrial proteins such as ATP synthases and ribosomal protein precursors, as measured by DNA microarrays. In the diabetic animal model, consumption of the Totala isolate resulted in decreased weight gain, blood glucose, and glycated hemoglobin. To our best knowledge, this is the first description ever of a fossil material having anti-diabetic activity in pre-clinical models.

Obesity among adults in the United States: No statistically significant change since 2003-2004

2007 ◽  
Author(s):  
Cynthia L. Ogden ◽  
Margaret D. Carroll ◽  
Margaret A. McDowell ◽  
Katherine M. Flegal
Keyword(s):  
United States ◽  
The United States ◽  
Significant Change

Presence and Possible Origin of ɛ(γ-Glutamyl)Lysine Isodipeptide in Human Plasma

1992 ◽  
Vol 67 (01) ◽  
pp. 060-062 ◽  
Author(s):  
J Harsfalvi ◽  
E Tarcsa ◽  
M Udvardy ◽  
G Zajka ◽  
T Szarvas ◽  
...  
Keyword(s):  
Human Plasma ◽  
Fibrinolytic Therapy ◽  
Normal Human Plasma ◽  
Normal Human ◽  
Hplc Technique ◽  
Significant Change

Summaryɛ(γ-glutamyl)lysine isodipeptide has been detected in normal human plasma by a sensitive HPLC technique in a concentration of 1.9-3.6 μmol/1. Incubation of in vitro clotted plasma at 37° C for 12 h resulted in an increased amount of isodipeptide, and there was no further significant change when streptokinase was also present. Increased in vivo isodipeptide concentrations were also observed in hypercoagulable states and during fibrinolytic therapy.

On the Behaviour of a Human Serum Proactivator Reacting with Streptokinase during Artificial Activation of the Fibrinolytic System

1961 ◽  
Vol 06 (03) ◽  
pp. 498-503 ◽  
Author(s):  
W Doleschel ◽  
W Auerswald
Keyword(s):  
Human Serum ◽  
Fibrinolytic System ◽  
Spontaneous Activation ◽  
Significant Change ◽  
Artificial Activation ◽  
Activator System

SummaryDuring “spontaneous” activation of a human euglobulin preparation in suitably spaced samples — while plasminogen became progressively converted into piasmin — the proactivator content was tested by addition of equal amounts of streptokinase and evaluation of the lytic activities on heated and normal bovine fibrin plates. Indepedently of the decreasing content of plasminogen the proactivator which could be activated by streptokinase showed no significant change of concentration. These observation indicate that plasminogen is not acting as proactivator and that there exists a separate proactivator-activator system of the fibrinolytic mechanism in human serum.

Sign in / Sign up

Export Citation Format

Share Document